Susanne Bremer
Susanne Bremer has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Francesca Pistollato
Institute for Health and Consumer Protection (IHCP), JRC, Ispra, Italy
3 shared publicationsDimitra Zagoura
Institute for Health and Consumer Protection (IHCP), JRC, Ispra, Italy
2 shared publicationsJochem Louisse
Institute for Health and Consumer Protection (IHCP), JRC, Ispra, Italy
2 shared publicationsAgapios Sachinidis
Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne, Cologne, Germany
1 shared publication- Agapios Sachinidis
Center of Physiology and Pathophysiology, Institute of Neurophysiology, University of Cologne, Robert-Koch-Str. 39, 50931 Cologne, Germany
1 shared publication Benedetta Accordi
Oncohematology Laboratory, Department of Woman and Child Health, University of Padova, Padova, Italy
1 shared publication
Latest Publications
- 1 November 2014
- Published by Elsevier in Toxicology Letters
- Vol. 231 (1) , 38-44
A comparative transcriptomic study on the effects of valproic acid on two different hESCs lines in a neural teratogenicity test system
- 1 November 2014
- Published by Elsevier in Toxicology Letters
- Vol. 231 (1) , 38-44
A comparative transcriptomic study on the effects of valproic acid on two different hESCs lines in a neural teratogenicity test system
- Open Access
- 1 October 2014
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 280 (2) , 378-388
Development of a pluripotent stem cell derived neuronal model to identify chemically induced pathway perturbations in relation to neurotoxicity: Effects of CREB pathway inhibition
- 1 October 2014
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 280 (2) , 378-388
Open AccessDevelopment of a pluripotent stem cell derived neuronal model to identify chemically induced pathway perturbations in relation to neurotoxicity: Effects of CREB pathway inhibition
- 8 October 2013
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 10 (1) , 39-50
Regenerative toxicology: the role of stem cells in the development of chronic toxicities
Human stem cell lines and their derivatives, as alternatives to the use of animal cells or cancer cell lines, have been widely discussed as cellular models in predictive toxicology. However, the role of stem cells in the development of long-term toxicities and carcinogenesis has not received great attention so far, despite growing evidence indicating the relationship of stem cell damage to adverse effects later in life. However, testing this in vitro is a scientific/technical challenge in particular due to the complex interplay of factors existing under physiological conditions. Current major research programs in stem cell toxicity are not aiming to demonstrate that stem cells can be targeted by toxicants. Therefore, this knowledge gap needs to be addressed in additional research activities developing technical solutions and defining appropriate experimental designs. The current review describes selected examples of the role of stem cells in the development of long-term toxicities in the brain, heart or liver and in the development of cancer. The presented examples illustrate the need to analyze the contribution of stem cells to chronic toxicity in order to make a final conclusion whether stem cell toxicities are an underestimated risk in mechanism-based safety assessments. This requires the development of predictive in vitro models allowing the assessment of adverse effects to stem cells on chronic toxicity and carcinogenicity.
- 8 October 2013
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 10 (1) , 39-50
Regenerative toxicology: the role of stem cells in the development of chronic toxicities
Human stem cell lines and their derivatives, as alternatives to the use of animal cells or cancer cell lines, have been widely discussed as cellular models in predictive toxicology. However, the role of stem cells in the development of long-term toxicities and carcinogenesis has not received great attention so far, despite growing evidence indicating the relationship of stem cell damage to adverse effects later in life. However, testing this in vitro is a scientific/technical challenge in particular due to the complex interplay of factors existing under physiological conditions. Current major research programs in stem cell toxicity are not aiming to demonstrate that stem cells can be targeted by toxicants. Therefore, this knowledge gap needs to be addressed in additional research activities developing technical solutions and defining appropriate experimental designs. The current review describes selected examples of the role of stem cells in the development of long-term toxicities in the brain, heart or liver and in the development of cancer. The presented examples illustrate the need to analyze the contribution of stem cells to chronic toxicity in order to make a final conclusion whether stem cell toxicities are an underestimated risk in mechanism-based safety assessments. This requires the development of predictive in vitro models allowing the assessment of adverse effects to stem cells on chronic toxicity and carcinogenicity.
- 17 January 2012
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 8 (2) , 239-257
Standardization of pluripotent stem cell cultures for toxicity testing
(2012). Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opinion on Drug Metabolism & Toxicology: Vol. 8, No. 2, pp. 239-257.
- 17 January 2012
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 8 (2) , 239-257
Standardization of pluripotent stem cell cultures for toxicity testing
(2012). Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opinion on Drug Metabolism & Toxicology: Vol. 8, No. 2, pp. 239-257.
- 31 August 2010
- Published by Elsevier in Reproductive Toxicology
- Vol. 30 (1) , 161-199
The test chemical selection procedure of the European Centre for the Validation of Alternative Methods for the EU Project ReProTect
- 31 August 2010
- Published by Elsevier in Reproductive Toxicology
- Vol. 30 (1) , 161-199
The test chemical selection procedure of the European Centre for the Validation of Alternative Methods for the EU Project ReProTect